

CURRICULUM VITAE

Ehab L. Atallah MD

Professor

Department of Medicine

Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-4600
Email: eatallah@mcw.edu

EDUCATION:

12/1988 - 12/1994 M.D., School of Medicine, Cairo University, Cairo, Egypt
1988 University of London School Examination Board, Kano, Nigeria

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

03/1995 - 03/1996 Internship, Cairo University Hospitals, Cairo, Egypt
03/1996 - 03/1999 Resident, Medical Oncology & Radiotherapy, Cairo University, Cairo, Egypt
09/1999 - 06/2000 Assistant Lecturer of Clinical Oncology, Cairo University, Cairo, Egypt
07/2000 - 06/2003 Resident, Internal Medicine, Fairview Hospital, Cleveland Clinic Health System, Cleveland, OH
07/2003 - 06/2005 Fellow, Hematology/Oncology, Karmanos Cancer Institute, Detroit, MI
07/2005 - 06/2006 Chief Fellow, Hematology/Oncology, Karmanos Cancer Institute, Detroit, MI
07/2006 - 06/2007 Leukemia Fellow, MD Anderson Cancer Center, Houston, TX

FACULTY APPOINTMENTS:

07/2007 - 12/18/2010 Staff Physician, Zablocki Veterans Affairs Medical Center, Milwaukee, WI
07/2007 - 07/2014 Assistant Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
07/2014 - 07/2019 Associate Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
10/2018 - 10/2023 Hematological malignancies disease-oriented team lead, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
10/2018 - 09/2023 Section Head of Hematological Malignancies, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
01/2019 - Present Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

2009 - Present Member, Fellowship committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2009 - 2013 Committee of Intern Selection, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

2008 - Present Staff discussant, Hematologic malignancy tumor board, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2010 - 2022 Member, Oncology PNT Subcommittee, Medicine, Hematology and Oncology, Medical College

of Wisconsin, Milwaukee, WI
 2011 - 2012 Member, Antibiotic PNT Subcommittee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2012 Member, Leukemia Business Planning Committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2012 - 2013 Member, Cancer Center Working Group, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2014 - Present Member, Blood Management Committee FMLH, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2022 - Present Associate director of the cancer service line, Medicine, Hematology and Oncology, Froedtert Hospital / Medical College of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:

2013 - 2023 Co-chair, MCW Data Safety Monitoring Committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2017 Clinical Translational Pilot Grant Committee Member, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2021 American Cancer Society's Institutional Research Grant Review Committee
 2021 MCWCC Pilot Grant application, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
 2021 GSPMC/CC Joint Pilot Study Section

HOSPITAL STAFF PRIVILEGES:

07/2007 - Present Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Avenue, Milwaukee, WI 53226

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	08/2003	08/2013
Hematology	08/2006	08/2016
Oncology	08/2006	08/2016

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Wisconsin License	50252-20	07/01/2007	10/31/2025

AWARDS AND HONORS:

06/2001 Best First Year Resident, Fairview Hospital, Cleveland, OH
 07/2007 Merit award, ASCO Cancer Foundation
 03/2009 Dennis M. Bush Excellence in Teaching Award, Division of Hematology and Oncology, Medical College of Wisconsin
 06/2009 Teacher of the Year Award by Internal medicine residents, Medical College of Wisconsin
 2010 Best Ten Teaching Faculty Award by Internal Medicine Residents, Medical College of Wisconsin
 2014 Outstanding Medical Student Teacher Award, Medical College of Wisconsin
 2015 Department of Medicine Engstrom Murphy Award for Clinical Contribution, Medical College of Wisconsin
 2015 - 2023 The Best Doctors in America, Medical College of Wisconsin
 2016 Outstanding Medical Student Teacher Award, Medical College of Wisconsin
 2016 Faculty Development Award, Medical College of Wisconsin
 2017 MCW Program Mentor Award, Medical College of Wisconsin
 2017 Top Scores in Patient Satisfaction, Medical College of Wisconsin
 2021 Outstanding Medical Student Teacher Award, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

2007 - Present American Society of Hematology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorship

01/2018 - Present Overview of the treatment of chronic myeloid leukemia; Initial treatment of chronic myeloid leukemia in chronic phase

01/2018 - Present Accelerated phase CML: Diagnosis and treatment; Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy

Editorial Board

2017 - 2021 Leukemia Research

American Cancer Society

Oncology

Journal Review

American Journal of Hematology

Biology of Blood and Marrow Transplantation

Blood Advances

Blood (Journal of the American Society of Hematology)

Hematologica (Journal of the European Hematology Association)

Clinical Lymphoma, Myeloma and Leukemia

Cancer

Leukemia Research: Outstanding reviewer 2015: top 10th percentile in terms of the number of reviews completed for Leukemia Research in the past two years

Annals of Oncology

Clinical Leukemia

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

07/2018 Medical College of Wisconsin Faculty Council

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2015 Reviewer: Review research proposals for scientific relevance and merit, ASPIRE Oncology/Hematology Research Awards program, Pfizer ASPIRE Grants

11/2017 - Present Toxicity Monitor, Eastern Cooperative Oncology Group (ECOG)

2017 - Present Administrative director, H. Jean Khoury Cure CML Consortium

2017 Reviewer: Review research proposals for scientific relevance and merit, ASPIRE Oncology/Hematology Research Awards program, Pfizer ASPIRE Grants

2018 - Present Clinical basket chair for patients < 60 years old with AML, myeloMATCH precision medicine initiative

02/03/2023 - Present Steering Committee Chair, Phase II multi-center, open-label, single arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE)

03/29/2023 - Present Co-Chair, ECOG-ACRIN Leukemia

09/28/2023 - Present The iCMLf Scientific Advisory Board

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:**Active****Peer Review**

Title:	RAS pathway activation without acquisition of RAS mutation as a drug resistance mechanism in acute myeloid leukemia
Source:	2023 CTSI Traditional Pilot Award
Role:	Co-I (PI Karen Carlson, MD and, Nan Zhu, PHD)
PI:	Ehab Atallah
Dates:	06/01/2023 - 06/01/2024

Title:	A041703- Inotuzumab Ozogamicin & Blinatumomab in Patients w/ Newly
--------	--

	Diagnosed, Recurrent, or Refractory ALL
Source:	NCI-Alliance
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCRABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
Source:	ECOG/ACRIN
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Source:	ECOG/ACRIN
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with mIDH
Source:	Hutchison MediPharma
Role:	Institutional PI
PI:	Ehab Atallah, MD

Prior
Peer Review

Title:	Phase IIB, Multicenter, Randomized, open label Trial of CPX-351 (cytarabine:Daunorubicin) Liposome injection versus cytarabine and Daunorubicin in patients with untreated AML 60-75 years of age
Source:	Celator Pharm/CLTR0308-204
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	07/16/2009 - 07/15/2013
Direct Funds:	\$7,280
Title:	A Randomized Double-Blind, Placebo-controlled Study of the JAK inhibitor INCB018424 tablets administered orally to Subjects with Primary Myelofibrosis (DMF), post polycythemia vera-Myelofibrosis (PPV0MF) or Post Essential Thrombocythemia
Source:	PPD Development/INCB 18424-351
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	10/29/2009 - 10/28/2012
Direct Funds:	\$19,232

Title: A Randomized Double-Blind, Placebo-controlled Study of the JAK inhibitor INCB018424 tablets administered orally to Subjects with Primary Myelofibrosis (DMF), post polycythemia vera-Myelofibrosis (PPV0MF) or Post Essential Thrombocythemia

Source: PPD Development/INCB 18424-351

Role: Institutional PI

PI: Ehab Atallah, MD

Dates: 01/27/2010 - 01/26/2013

Direct Funds: \$19,513

Title: A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)

Source: ECOG

Role: Institutional PI

PI: Ehab Atallah, MD

Dates: 09/10/2010 - 2024

Title: Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)

Source: ECOG

PI: Ehab Atallah, MD

Dates: 04/21/2011 - 2024

Title: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine

Source: Onconova Therapeutics Inc

Role: Institutional PI

PI: Ehab Atallah, MD

Dates: 08/24/2011 - 2024

Title: A Phase III Randomized Study of Oral

	Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Source:	Cyclacel
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	10/13/2011 - 2024
Title:	A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Source:	ECOG
PI:	Ehab Atallah, MD
Dates:	08/02/2012 - 2024
Title:	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Source:	Gilead sciences
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	2012 - 2024
Title:	Protocol I3X-MC-JHTC(a) A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients with Myeloproliferative Neoplasms
Source:	Lilly
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	05/06/2013 - 2024
Title:	Phase II two-stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate, administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Source:	Sanofi
Role:	Institutional PI
PI:	Ehab Atallah, MD
Dates:	06/10/2013 - 2024
Title:	The Life After Stopping Tyrosine Kinase Inhibitors (The LAST study)
Role:	Co-PI with Kathryn Flynn, PhD

PI:	Ehab Atallah
Dates:	09/19/2014 - 08/31/2021
Title:	Peripheral Blood and Bone Marrow Collection for Optimizing T-cell Adoptive Cell Transfer for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Source:	Advancing a healthier Wisconsin
Role:	Co-I
PI:	Ehab Atallah
Dates:	02/01/2017 - 01/31/2019
Title:	A pilot study to investigate the hypomethylating properties of freeze-dried black raspberries (BRBs) in patients with myelodysplastic syndrome
Source:	Medical College of Wisconsin (MCW) Cancer Center and Froedtert Hospital Foundation
Role:	PI
PI:	Ehab Atallah
Dates:	05/01/2017 - 04/30/2019
Direct Funds:	\$149,342
Title:	National chronic myeloid leukemia registry
Source:	MCW Cancer Center
Role:	Co-PI (Atallah-Flynn)
PI:	Ehab Atallah, MD
Dates:	04/01/2018 - 03/31/2019
Title:	Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) for Underrepresented Minority Students
Role:	Co-Investigator
PI:	Janet Rader
Dates:	09/18/2018 - 08/31/2023
Title:	A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) Role in project: Principle investigator
Source:	Medical College of Wisconsin Cancer Center
Role:	Principle investigator
PI:	Ehab Atallah, MD
Title:	HJKC3-0005: H. Jean Khoury Cure CML Consortium (HJKC3) Registry
Source:	H Jean Khoury Cure CML Consortium
Role:	National PI (co-PI Kathryn Flynn, PHD)
PI:	Ehab Atallah, MD

Title:	Protocol CA180399: An Open Label, Randomized Phase 2B Study Of Dasatinib Vs. Imatinib In Patients With Chronic Phase Chronic Myeloid leukemia Who Have Not Achieved An Optimal Response To 3 Months Of Therapy With 400 Mg Imatinib
Source:	BMS
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Source:	Gilead sciences
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Protocol I3X-MC-JHTB(a) A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
Source:	Lilly
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase I, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML), or Patients with CD25-positive AML who are not Candidates for Treatment with Hypermethylating Agents
Source:	ADC Therapeutics
PI:	Ehab Atallah, MD
Title:	INCB053914 in Subjects With Advanced Malignancies
Source:	Incyte
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase III Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Source:	Astellas Pharma Global Development, Inc./APGD
Role:	Institutional PI
PI:	Ehab Atallah, MD

Title:	Phase III, Multicenter, Randomized, Trial Of CPX-351(cytarabine:daunorubicin) Liposome Injection Versus Cytarabine And Daunorubicin In Patients 60-75 Years Of Age With Untreated High Risk (Secondary) AML
Source:	Celator Pharmaceuticals, Inc.
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase II Open-Label, Single-Arm, Two-Stage, Multicenter Trial Of Pracinostat In Combination With Azacitidine In Elderly (age 65 plus Years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Source:	MEI Pharma
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High-risk Myelodysplastic Syndrome (MDS)
Source:	Seattle Genetics
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Source:	MedImmune, LLC
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	ALLIANCE-A041501- A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
Source:	ECOG/ACRIN
PI:	Ehab Atallah, MD
Title:	A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and

Role:	Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease
PI:	Study Vice Chair Ehab Atallah, MD
Title:	Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders
Source:	ECOG/ACRIN
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Source:	Takeda and Abbvie
Role:	Principle Investigator (Co-PI Dr. Guru Subramanian Guru Murthy)
PI:	Ehab Atallah, MD
Title:	Assessment of allogeneic hematopoietic stem cell transplantation in Medicare Beneficiaries with myelodysplastic syndrome and related disorders
Source:	CIBMTR
Role:	PI
PI:	Ehab Atallah, MD
Title:	HJKC3-0006: Real World Outcome of Patients with CML Treated on Second Line or Later Therapy
Source:	H Jean Khoury Cure CML Consortium/Takeda
Role:	PI (co-PI Kathryn Flynn, PhD, James Thompson, MD, Michael Mauro, MD)
PI:	Ehab Atallah, MD
Title:	A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia
Source:	Gilead Sciences
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase III, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab versus Chemotherapy in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Source:	Amgen
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Multi-Center, Open-Label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib
Source:	Novartis
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	HKC3-0004: Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Source:	H Jean Khoury Cure CML Consortium/Novartis
Role:	Institutional PI, steering committee (Jorge Cortes, MD PI)
PI:	Ehab Atallah, MD
Title:	Clavis_CP4055-306: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia
Source:	Clavis_CP4055-306
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	HKC3-0002: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Source:	H Jean Khoury Cure CML Consortium/Incyte
Role:	Institutional PI and administrative director
PI:	Ehab Atallah, MD
Title:	KRT-232 and TKI Study in Chronic Myeloid Leukemia
Source:	Kartos
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk
Source:	AstraZeneca
Role:	Institutional PI

PI:	Ehab Atallah, MD
Title:	HJKC3-0007: Real World Outcomes of Patients with CML-CP Treated with Asciminib and Other Tyrosine Kinase Inhibitors (Novartis funded, 5 years)
Source:	H Jean Khoury Cure CML Consortium/Takeda
Role:	PI (co-PI Kathryn Flynn, PhD, James Thompson, MD, Michael Mauro, MD)
PI:	Ehab Atallah, MD
Title:	A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents
Source:	MEI Pharma
Role:	National PI
PI:	Ehab Atallah, MD
Title:	Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)
Source:	Novartis
Role:	National PI
PI:	Ehab Atallah, MD
Title:	A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Source:	ADC Therapeutics
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in elderly subjects with treatment Refractory or Relapsed Acute Myeloid Leukemia Quintiles/CHR – 2797-038
Source:	Quintiles/CHR – 2797-038
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes

Source:	Incyte
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Source:	ECOG/ACRIN
PI:	Ehab Atallah, MD
Title:	A Phase II Randomized, Multicenter Study Of Treatment-Free Remission In Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Patients Who Achieve And Sustain MR4.5 After Switching To Nilotinib
Source:	Novartis
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Phase I of modified VXLD plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia
Source:	Research grant from Millenium
Role:	Investigator
PI:	Ehab Atallah, MD
Title:	A Phase I/II Study of Lintuzumab-Ac225 In Older Patients with Untreated Acute Myeloid Leukemia
Source:	Actinium Pharmaceuticals, Inc.
PI:	Ehab Atallah, MD
Title:	A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension)
Source:	GSK

Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Source:	Covance
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Source:	ECOG/ACRIN
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase 1 study of XmAb18968 (CD3-CD38) for the treatment of patients with relapsed/refractory acute leukemia and T cell lymphoblastic lymphoma
Source:	Xencor
Role:	Principle Investigator (Co-PI Dr. Guru Subramanian Guru Murthy)
PI:	Ehab Atallah, MD
Title:	Incyte-Jak-2-351 A Randomized, Double Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
Source:	PPD Development
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Tolero-TOI-ALV-201: A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML
Source:	Tolero Pharmaceuticals, Inc
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	A Phase III Randomized Trial of

Source:	Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults ECOG/ACRIN
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Phase I of Standard Maintenance plus MLN9708 Maintenance Therapy in adults with Acute Lymphoblastic Leukemia in Complete Remission
Source:	Research grant from Millennium
Role:	PI
PI:	Ehab Atallah, MD
Title:	A Phase II Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Source:	Acerta Pharm
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	HKC3-0003: Treatment Free Remission After Combination Therapy With Asciminib Plus Imatinib
Source:	H Jean Khoury Cure CML Consortium/Novartis
Role:	National PI and administrative director (Michael Mauro, MD study chair)
PI:	Ehab Atallah, MD
Title:	Eradicating Measurable Residual disease in patients with AML prior to StEm cell transplantation
Source:	ECOG/NCI/Myelomatch
Role:	PI
PI:	Ehab Atallah, MD
Title:	A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Source:	Avillion
Role:	Institutional PI
PI:	Ehab Atallah, MD
Title:	Open Label Ib/IIa Trial of a Combination of IPH2201 and Ibrutinib in Patients with Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Source:	Innate Pharma
Role:	Institutional PI
PI:	Ehab Atallah, MD

Title:	Onconova 09-08: Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Source:	Onconova Therapeutics, Inc
Role:	Institutional PI
PI:	Ehab Atallah, MD

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local

Ehab Atallah, MD, Hematology Update Meeting, Milwaukee, WI, 2009 - 2011

Ehab Atallah, MD, Leukemia: Have we made progress, Grand Rounds, FMLH, The Department of Medicine, 03/04/2011

Ehab Atallah, MD, First Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/24/2012

Ehab Atallah, MD, Second Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/09/2013

Ehab Atallah, MD, Leukemia for primary care, Columbia St. Mary's grand rounds, Milwaukee, WI, 09/24/2013

Ehab Atallah, MD, Third Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/08/2014

Ehab Atallah, MD, Hematology and Leukemia, Family nurse practitioner doctorate class, University of Wisconsin-Milwaukee College of Nursing Hematology and Leukemia, 09/02/2015

Ehab Atallah, MD, Leukemia for the FISHers and Karyotypers, MCW cytogenetics lab, 04/03/2017

Ehab Atallah, MD, CML, MCW Cancer center board of directors meeting, MCW Cancer center, 12/13/2017

Ehab Atallah, MD, To transplant or not to transplant: That is the question, BMT education, MCW, 05/10/2018

Ehab Atallah, MD, CML: An Update, Eighth Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/09/2019

Ehab Atallah, MD, Intensive vs. Less Intensive therapy in AML, Ninth Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/01/2020

Ehab Atallah, MD, Frankly speaking about leukemia, Gildas club, 10/13/2021

Ehab Atallah, MD, CML Updates, Pediatric Tumor Board, Children's Hospital of Wisconsin

Regional

Ehab Atallah, MD, AML, CME lecture, Fond du Lac Cancer center, 01/29/2013

Ehab Atallah, MD, CML, CME program, Elmbrook Hospital, 05/21/2013

Ehab Atallah, MD, Inaugural Leukemia Survivorship conference, Oshkosh, WI, 02/21/2015

Ehab Atallah, MD, Conversations with Scientists: Cancer- Past, Present and Future, Advancing a Healthier Wisconsin program, 05/11/2016

AA & MDSIF Bone Marrow Failure Disease Symposium, WI, 11/04/2016

Ehab Atallah, MD, -CML: 9/24/16 -CML: 9/23/17 -CML: 9/22/18 -CLL Emerging Therapies: 9/21/19 -CML: 10/16/20, Leukemia, Lymphoma Society Blood Cancer Conference, WI, 2016 - 2020

Ehab Atallah, MD, Understanding the CTO protocol development process, Investigator initiated trials. Boot Camp series, 02/17/2017

Ehab Atallah, MD, How can we improve CML therapy?, grand rounds, University of Wisconsin Cancer Center, 01/23/2018

Ehab Atallah, MD, The Divide between Clinical Research and Clinical Practice, Fifth annual clinical research symposium, 10/05/2018

Ehab Atallah, MD, AML: An update, Seventh annual advances in hematology and oncology fall symposium, 11/10/2018

Ehab Atallah, MD, Hematologic Malignancies,, OncLive® State of the Science Summit, Milwaukee, WI, 04/23/2019

Ehab Atallah, MD, Updates on AML, grand rounds, St. Vincent Hospital, Green Bay, WI, 09/11/2020

Ehab Atallah, MD, Leukemia for primary care, Watertown clinic, 10/01/2020
 Ehab Atallah, MD, Why is there no standard of care in relapsed/refractory AML?, Acute Leukemia Forum 2020, 10/15/2020
 Ehab Atallah, MD, Leukemia/Lymphoma, Onclive Institutional Perspectives in Cancer, 05/20/2021
 Ehab Atallah, MD, Cancer Prevention & Outcomes Research Program. Curing CML: Where do we go from here?, MCWS Cancer Center Seminar Series, 09/24/2021
 Ehab Atallah, MD, Updates on Leukemia, St. Agnes Hospital, 10/12/2022
 Ehab Atallah, MD, Progress in Myeloid malignancies: Case presentations, 11th Annual Advances in Hematology and Oncology Fall Symposium, 10/29/2022
 Ehab Atallah, MD, Leukemia, Lymphoma Society: National Blood Cancer Conference, 09/09/2023
 Ehab Atallah, MD, OncLive® State of the Science Summit, 09/20/2023
 Ehab Atallah, MD, Myelodysplastic Syndrome, Oncology Lecture Series, Bellin Health, 11/29/2023

National

Ehab Atallah, MD, Leukemia: Have We Made Progress?, Grand rounds: Chicago Medical School at Rosalind Franklin, Chicago, IL, 09/23/2009
 Ehab Atallah, MD, Cincinnati VA Medical Center grand rounds, Cincinnati, OH, 3/24/2010 Aleda E Lutz VA Medical Center grand rounds, Saginaw, MI, 4/30/2010 VA Western NY Medical Center grand rounds, Buffalo, NY, 5/12/2010 VA Pittsburgh Healthcare System grand rounds, Pittsburgh, PA, 5/18/2010 Louis A Johnston VA grand rounds, Clarksburg, WV, 7/7/2010, CML, CME lecture series, 2010 - 2012
 Ehab Atallah, MD, Myeloproliferative neoplasms, Grand rounds: Chicago Medical School at Rosalind Franklin, Chicago, IL, 06/01/2011
 Ehab Atallah, MD, New Advances in Oncology AML: The case for 7 +3, Update in Chronic Lymphocytic Leukemia, Marquette General Hospital, MI, 05/04/2012
 Ehab Atallah, MD, COMFORT-I Publication Steering Committee, 08/18/2012
 Ehab Atallah, MD, Myelodysplastic syndrome: Have we made any progress, Advances in Hematology and oncology-Green Bay symposium, 10/06/2012
 Ehab Atallah, MD, The Confusing Treatment Landscape in CML: A Welcome Development, Northwestern University's Grand Rounds Lecture Series, 04/04/2014
 Ehab Atallah, MD, Acute Promyelocytic Leukemia, The 42nd Annual Dameshek Symposium, Wichita, Kansas, 05/16/2014
 Ehab Atallah, MD, Chair of the Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant (Oral Abstract Session), 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, 06/06/2016
 Ehab Atallah, MD, Collaborative Approaches to the Treatment of CML, CME lecture series, Inova Alexandria Hospital, 2/24/16 The George Washington University Hospital, 4/29/16 LSU Health Sciences Center - Feist Weiller Cancer Center, 5/20/16 Rush University Medical Center, 6/1/16, 2016
 Ehab Atallah, MD, Chair Educational Session: Chronic Myeloid Leukemia: What Every Practitioner Needs to Know, ASCO 2017, 06/03/2017
 Ehab Atallah, MD, Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Is It Ready for Prime Time?, ASCO 2017, 06/03/2017
 Ehab Atallah, MD, CML Monitoring and TKI Discontinuation, Charles L. Spurr Piedmont Oncology Symposium, Wake Forest School of Medicine, 09/16/2017
 Ehab Atallah, MD, Chair Treatment of CML session: 10th International Congress. Myeloproliferative neoplasms and Chronic Myeloid Leukemia, Diagnosis, Management and new clinical developments, New York, NY, 10/03/2017
 Ehab Atallah, MD, 10th International Congress. Myeloproliferative neoplasms and Chronic Myeloid Leukemia, Diagnosis, Management and new clinical developments. Generic Imatinib vs. second generation TKIs, New York, NY, 10/03/2017
 Ehab Atallah, MD, ASH Review: Current Updates in Hematologic Diseases, CML-An update, University of Kansas, 02/10/2018
 Ehab Atallah, MD, Chair of the Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant, American Society of Clinical Oncology (ASCO) Annual Meeting, 06/02/2018
 Ehab Atallah, MD, 20th Annual John Goldman Conference on Chronic Myeloid Leukemia, European Society of Hematology, Miami, FL, 09/13/2018 - 09/16/2018
 Ehab Atallah, MD, OncLive® State of the Science Summit: Hematologic Malignancies, CML-Treatment Free

Remission, 09/13/2018

Ehab Atallah, MD, Subject Matter Expert, ASCO Advantage, 01/03/2019

Ehab Atallah, MD, Can we improve CML outcome?, Houston Methodist Oncology Grand Rounds, 04/02/2019

Ehab Atallah, MD, Focus on Leukemias, Lymphomas, and Myeloma Treatment Discontinuation in CML: Dos and Don'ts, 24th Annual International Congress on Hematologic Malignancies®, Miami, FL, 03/01/2020

Ehab Atallah, MD, Debate: What is the Main Objective of Therapy in CML? Treatment Free Remission; Who May Benefit From A 2nd Generation TKI In First Line Management Of Chronic Phase CML?, Virtual Great Debates & Updates in Hematologic Malignancies, 08/29/2020

Ehab Atallah, MD, Current research in CML and the impact of COVID-19, iCMLf webinar, 09/22/2020

Ehab Atallah, MD, SOHO Session Chair: General Session VI CML, 09/09/2021

Ehab Atallah, MD, Chair of the Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | Satellite Symposium, 8th Annual Congress of The European Society for Translational Medicine, 09/23/2021

Ehab Atallah, MD, Special education session on collaborative Hematology Networks, ASH, The H. Jean Khoury Cure CML Consortium, 2021

Ehab Atallah, MD, Spotlight on CML, Leukemia, Lymphoma Society, 09/28/2022

Ehab Atallah, MD, The New + Emerging Treatments: CML, Leukemia Research Foundation, 10/12/2022

Ehab Atallah, MD, Update on Management of CML: New Agents and Monitoring for MRD, Lymphoma, Leukemia and Myeloma, New York, New York, 10/19/2022

Ehab Atallah, MD, Leukemia, Lymphoma Society: Upper Midwest Blood Cancer Conference, Minneapolis, MN, 11/05/2022

Ehab Atallah, MD, ASH/FDA Joint Symposium on Late Breaking Drug Approvals, 64th ASH Annual Meeting and Exposition, 12/2022

Ehab Atallah, MD, iCMLf Key Discussions in CML: The realities of Treatment Free Remission in Low and Middle Income Countries, 04/2023

Ehab Atallah, MD, Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches, Ash 2023, 12/11/2023

Ehab Atallah, MD, Are we curing Leukemia yet?, Grand Rounds Fairview Hospital, Cleveland OH, 12/2027

International

Ehab Atallah, MD, 5th International Congress on Leukemia Lymphoma Myeloma, Turkish Society of Hematology 2015, CML: Molecular Monitoring and Treatment-free Remissions, Istanbul, Turkey, 05/21/2015 - 05/23/2015

Ehab Atallah, MD, 24th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, The LAST Trial: The Value of PRO After Treatment Discontinuation, Mandelieu- La Napoule, France, 10/21/2022 - 10/23/2022

Ehab Atallah, MD, Biology and Therapy, 25th Annual John Goldman Conference on Chronic Myeloid Leukemia, Mandelieu- La Napoule, France, 10/06/2023 - 10/08/2023

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

National

Atallah E , Kantarjian H , O'Brien S , Jones D , Borthakur G Nicaise C , Cortes J. Dasatinib, (SPRYCEL ®) is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase, American Society of Clinical Oncology Meeting, Chicago, 06/2007

Verstovsek S, Atallah E, Thomas D, Cortes J, Ravandi-Kashani F, Nicaise C, Sams I, Giles F, Kantarjian H. Dasatinib, Therapy for Patients with Philadelphia negative Myeloproliferative Disorders Including Systemic Mastocytosis, ASCO, 2007

Olatoyosi Odenike, Emily Curran, Neil Iyengar, Leslie Popplewell, Mark Kirschbaum, Harry P Erba, Margaret Green, Xavier Poiré, Pamela Ihonor, Ernesto Diaz-Flores, Kevin Shannon, Ehab Atallah, James L Wade, III, Maria Perdekamp, Sreenivasa Nattam, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Elizabeth Shima Rich, Richard A. Larson, and Wendy Stock, Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML), Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2081

Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Donna Di

- Gravio, Lisa Pyle, Syed Rizvi, and Jean-Pierre J Issa, Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study, Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2089
- T.A. Giever, K.M. Adwan, Y. Cheng, E.L. Atallah, Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy, J Clin Oncol 28:15s, 2010 (suppl;abstr 9033)
- Atallah E, Durand J, Kantarjian H, Jabbour E, O'Brien S, Rios M, Cortes J., Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy, Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2146
- Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S, Kornblau S, Cortes J., Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML), Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1035
- Atallah E, Verstovsek S., Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RA-RST) is a Favo, Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2612
- Kirschbaum M, Gojo I, Goldberg S, Kujawski L, Atallah E, Marks P, Garcia-Vargas J, Rizvi S, Di Gravio D, Ahern J and Issa JP, Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Blood (ASH Annual Meeting Abstracts), Dec 2008; 112: 3651

MEDICAL COLLEGE TEACHING ACTIVITIES:

Medical Student Education

- 2008 - Present Clinical preceptorship: Ambulatory immersion rotation for medical students
- 2010 - 2012 Instructor in the "General Principles" Module of the M1 Curriculum, "Neoplasia and Carcinogenesis"
- 2011 Preceptor for CER History & Physical for M2 students
- 2012 Instructor in the "General Principles" Module of the M2 Curriculum, "Neoplasia and Carcinogenesis"
- 2013 - 2015 Clinical Apprenticeship Preceptor
- 2014 - 2021 Instructor in the "Heme/lymph" Module of the M2 Discovery Curriculum
- 2015 Molecules to cells case based discussions

Resident and Fellow Education

- 03/17/2009 Fellows Core curriculum lecture CLL
- 03/24/2009 Fellows Core Curriculum lecture CML
- 05/06/2009 Resident Core curriculum lecture: Chronic Leukemia and myeloproliferative neoplasms
- 10/19/2010 Core Education Session – CLL
- 01/25/2011 Core Education Session - CML
- Fellows Clinical preceptorship -Jenny Petkova, Leena Varkey and Sunita Sukumaran
- Resident Clinical preceptorship: Ambulatory clinical rotations for residents

Nursing Student Education

- 03/2009 Leukemia for Nurses
- 01/08/2013 1/8/2013 Leukemia for Nurses. What you need to know
- 11/2014 Therapy related AML
- 12/06/2017 Therapy related AML

EXTRAMURAL TEACHING:

Community/Lay Public

- Chronic Lymphocytic Leukemia Support Group in Wisconsin: Sponsor
- Milwaukee CML connection. National CML society: Sponsor

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Medical Students

Vernon M, Medical College of Wisconsin, 08/2009 Research Advisor, Resolution of rheumatoid arthritis symptoms with imatinib mesylate. *Journal of clinical Rheumatology*. 15(5):267

Clinical/Research Fellows

Randhawa, J., Medical College of Wisconsin, 08/2014 Research mentorship and protocol writing,

Myelodysplastic syndrome. Hospital Physician. Hematology Board Review Manual. Volume 9, Part 3

Peswani N., Medical College of Wisconsin, 10/30/2014 - 11/01/2014 Research mentorship and protocol writing, D-Dimer Kinetics, Chemotherapy And The Risk Of Bleeding In Patients With Acute Promyelocytic Leukemia. Congress on Controversies in Thrombosis and Hemostasis (CiTH). Berlin, Germany

Peswani N., Medical College of Wisconsin, Research mentorship and protocol writing, D-Dimer Kinetics, Chemotherapy and Risk of Bleeding in Acute Promyelocytic Leukemia (*Blood* 2014 124:1490)

Badar T, Medical College of Wisconsin, Research mentorship and protocol writing, Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. *Clin Lymphoma Myeloma Leuk*. 2020 Aug;20(8):556-560.e2. doi: 10.1016/j.clml.2020.03.004. Epub 2020 Mar 19. PMID: 32291234

Guru, M, Medical College of Wisconsin, Research mentorship and protocol writing, A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and secondary Acute Myeloid Leukemia (AML)

Badar T, Medical College of Wisconsin, Research mentorship and protocol writing, Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. *Blood Adv*. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381. PMID: 32453836

Randhawa, J, Medical College of Wisconsin, Research mentorship and protocol writing, Phase I study combining POMP (Prednisone, vincristine, methotrexate and 6-mercaptopurine) maintenance therapy with and oral proteasome inhibitor MLN9708.

Badar T, Medical College of Wisconsin, Research mentorship and protocol writing, Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. *Bone Marrow Transplant*. 2021 Apr 6. doi: 10.1038/s41409-021-01279-w. Epub ahead of print. PMID: 33824440.

Badar T, Medical College of Wisconsin, Research mentorship and protocol writing, Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. *Cancer*. 2020 Dec 1. doi: 10.1002/cncr.33340. Epub ahead of print. PMID: 33259056.

Guru, M., Medical College of Wisconsin, Research mentorship and protocol writing, Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States. *Blood* 2017 130:2575

Guru, M, Medical College of Wisconsin, Research mentorship and protocol writing, Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States. *Blood* 2017 130:2578;

Residents

Angel, J. R., Medical College of Wisconsin, 2010 Research Advisor, Recurrent deep vein thrombosis and pulmonary embolism in a young man with klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298>C. *Blood Coagulation & Fibrinolysis: An international Journal in Haemostasis and Thrombosis*, 21(4), 372-375

Bilgi N., Medical College of Wisconsin, Research Advisor, Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. 2010 May;44(5):926-8.

Jasleen K., Medical College of Wisconsin, Research Advisor, Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 4157

Faculty

Guru M, Medical College of Wisconsin, Research Mentoring and protocol writing, SH CRTI project.

Assessment of the role of frailty and comorbid conditions on the outcomes of adult patients with acute lymphoblastic leukemia. Role: Institutional mentor

Guru M (Co-PI), Medical College of Wisconsin, Research Mentoring and protocol writing, Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE)

Narra RK, Medical College of Wisconsin, Research Mentoring and protocol writing, Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. *Curr Hematol Malig Rep*. 2017 Sep 25. PubMed PMID: 28944397.

Abedin S, Medical College of Wisconsin, Research Mentoring and protocol writing, Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Abedin S., Medical College of Wisconsin, Research Mentoring and protocol writing, Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:

Residents

T.A. Giever, Medical College of Wisconsin, Milwaukee, WI: Clement J. Zablocki V.A. Medical Center, Milwaukee, WI, Research Advisor, Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy. *J Clin Oncol* 28:15s, 2010 (suppl;abstr 9033)

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. **Atallah E**, Talpaz M, O'Brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic Myelogenous Leukemia In T Cell Lymphoid Blastic Phase Achieving Durable Complete Cytogenetic And Molecular Remission With Imatinib Mesylate (STI571; Gleevec) Therapy. *Cancer* 2002; 94(11):2996-2999.
2. **Atallah E**, Durand J, Kantarjian H, Cortes J. Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy. *Blood*. 2007 Aug 15;110(4):1233-7
3. **Atallah E**, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of Baseline Toxicity Expectations with Standard Frontline Chemotherapy in Acute Myelogenous Leukemia. *Blood*. 2007 Nov 15;110(10):3547-51.
4. Nand, J, Bryke C, Divgi A, Kroft S, Bredeson C, **Atallah E**. Myeloproliferative Disorder with Eosinophilia and ETV6-ABL Gene Rearrangement: Efficacy of Second Generation Tyrosine Kinase Inhibitors. *Leukemia Research*. 2009 Aug;33(8):1144-6. Epub 2009 Apr 25.
5. Bilgi N, Bell K, Ananthakrishnan AN, **Atallah E**. *Ann Pharmacother*. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. 2010 May;44(5):926-8. Epub 2010 Mar 23.
6. Olteanu H, Schur BC, Bredeson C, **Atallah E**, Kroft SH. Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. *Leuk Lymphoma*. 2010 Mar;51
7. Atallah, E., Abrams, J., Ayash, L., Bentley, G., Abidi, M., Ratanatharathorn, V., et al. (2010). Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. *American Journal of Hematology*, 85(8): 579-83.
8. Angel, J. R., Parker, S., Sells, R.E., & Atallah, E. (2010). Recurrent deep vein thrombosis and pulmonary embolism in a young man with klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298>C. *Blood Coagulation & Fibrinolysis: An international Journal in Haemostasis and Thrombosis*, 21(4), 372-375.
9. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, **Atallah E**, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. *Am J Hematol*. 2017 Sep;92(9):E563-E565.
10. Khoury HJ, Williams LA, **Atallah E**, Hehlmann R. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. *Am Soc Clin Oncol Educ Book*. 2017;37:468-479.
11. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M,

- Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, **Atallah E**, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. *J Clin Oncol*. 2017 Aug 20;35(24):2745-2753. PMID: PMC5562170
12. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, **Atallah E**, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1295-1302.
 13. Talpaz M, Saglio G, **Atallah E**, Rousselot P. Dasatinib dose management for the treatment of chronic myeloid leukemia. *Cancer*. 2018 Apr 15;124(8):1660-1672. PMID: PMC5901015
 14. **Atallah E**, Ritchie E. Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? *Expert Opin Pharmacother*. 2018 Feb;19(2):79-81.
 15. **Atallah E**, Schiffer CA. Granulocyte transfusion. *Curr Opin Hematol*. 2006 Jan;13(1):45-9.
 16. Narra RK, Flynn KE, **Atallah E**. Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. *Curr Hematol Malig Rep*. 2017 Oct;12(5):415-423. PMID: PMC6045428
 17. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, **Atallah E**, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2016 Apr;17(4):496-508.
 18. Flynn KE, **Atallah E**. Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. *Curr Hematol Malig Rep*. 2016 Apr;11(2):80-5. PMID: PMC4860261
 19. **Atallah E**, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. *BMC Cancer*. 2018 Apr 02;18(1):359. PMID: PMC5879565
 20. Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, **Atallah E**, Hari P, Carlson K. Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. *Acta Haematol*. 2018;139(3):171-175. PMID: PMC6388419
 21. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, **Atallah E**. Incidence and survival of therapy related myeloid neoplasm in United States. *Leuk Res*. 2018 Aug;71:95-99.
 22. Voshtina E, Huang H, Raj R, **Atallah E**. Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. *Case Rep Hematol*. 2018;2018:6514604. PMID: PMC6092972
 23. **Atallah E**, Talpaz M, O'Brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. *Cancer*. 2002 Jun 01;94(11):2996-9.
 24. **Atallah E**, Flaherty L. Treatment of metastatic malignant melanoma. *Curr Treat Options Oncol*. 2005 May;6(3):185-93.
 25. **Atallah E**, Schiffer CA. Agent Orange, prostate cancer irradiation and acute promyelocytic leukemia (APL): is there a link? *Leuk Res*. 2007 May;31(5):720-1.
 26. **Atallah E**, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. *Expert Opin Pharmacother*. 2007 Jan;8(1):65-73.
 27. **Atallah E**, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. *Nat Med*. 2007 Jan;13(1):14; author reply 15-6.
 28. **Atallah E**, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Curr Opin Hematol*. 2007 Mar;14(2):138-44.
 29. **Atallah E**, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. *Clin Lymphoma Myeloma*. 2007 Mar;7 Suppl 3:S105-12.
 30. **Atallah E**, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. *Blood*. 2007 Aug 15;110(4):1233-7.
 31. **Atallah E**, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ,

- Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. *Blood*. 2007 Nov 15;110(10):3547-51.
32. **Atallah E**, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. *Clin Adv Hematol Oncol*. 2007 Jul;5(7):544-52.
33. **Atallah E**, Nussenzweig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. *Leukemia*. 2008 Jun;22(6):1295-8.
34. **Atallah E**, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. *Cancer Invest*. 2008 Mar;26(2):208-16.
35. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, **Atallah E**. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. *Leuk Res*. 2009 Aug;33(8):1144-6.
36. **Atallah E**, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. *Expert Rev Anticancer Ther*. 2009 May;9(5):663-70. PMID: PMC5176249
37. O'Dwyer M, **Atallah E**. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. *Semin Hematol*. 2009 Apr;46(2 Suppl 3):S16-21.
38. Vernon MR, Pearson L, **Atallah E**. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. *J Clin Rheumatol*. 2009 Aug;15(5):267.
39. Olteanu H, Schur BC, Bredeson C, **Atallah E**, Kroft SH. Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. *Leuk Lymphoma*. 2010 Mar;51(3):481-7.
40. Bilgi N, Bell K, Ananthakrishnan AN, **Atallah E**. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. *Ann Pharmacother*. 2010 May;44(5):926-8.
41. Angel JR, Parker S, Sells RE, **Atallah E**. Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. *Blood Coagul Fibrinolysis*. 2010 Jun;21(4):372-5.
42. **Atallah E**, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J. Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. *Am J Hematol*. 2010 Aug;85(8):579-83. PMID: PMC3800118
43. **Atallah E**. Nilotinib cardiac toxicity: should we still be concerned? *Leuk Res*. 2011 May;35(5):577-8.
44. Kim J, Haddad RY, **Atallah E**. Myeloproliferative neoplasms. *Dis Mon*. 2012 Apr;58(4):177-94.
45. Torgerson SR, Haddad RY, **Atallah E**. Chronic myelogenous leukemia for primary care physicians. *Dis Mon*. 2012 Apr;58(4):168-76.
46. Randhawa J, Ostojic A, Vrhovac R, **Atallah E**, Verstovsek S. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. *J Hematol Oncol*. 2012 Aug 01;5:43. PMID: PMC3464878
47. Randhawa J, Wong S, **Atallah E**, Olasz E. Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. *Int J Dermatol*. 2014 Jan;53(1):e13-4.
48. **Atallah E**, Verstovsek S. Emerging drugs for myelofibrosis. *Expert Opin Emerg Drugs*. 2012 Dec;17(4):555-70. PMID: PMC5009610
49. Saber W, Cutler CS, Nakamura R, Zhang MJ, **Atallah E**, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). *Blood*. 2013 Sep 12;122(11):1974-82. PMID: PMC3772501
50. Kremianskaya M, **Atallah EL**, Hoffman R, Mascarenhas JO. Clarifying the use of ruxolitinib in patients with myelofibrosis. *Oncology (Williston Park)*. 2013 Jul;27(7):706-14.
51. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, **Atallah EL**, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. *Clin Cancer Res*. 2014 Jan 15;20(2):490-8. PMID: PMC4310865
52. Verstovsek S, Gotlib J, Gupta V, **Atallah E**, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis

- treated with ruxolitinib and effect of dose modifications on efficacy outcomes. *Onco Targets Ther.* 2013;7:13-21. PMID: PMC3869911
53. **Atallah E**, Bylow K, Troy J, Saber W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). *Curr Hematol Malig Rep.* 2014 Mar;9(1):57-65. PMID: PMC4031643
 54. Kantarjian HM, Lioure B, Kim SK, **Atallah E**, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk.* 2016 Mar;16(3):139-45. PMID: PMC5557033
 55. Hanif A, Hari PN, **Atallah E**, Carlson KS, Pasquini MC, Michaelis LC. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. *Bone Marrow Transplant.* 2016 Apr;51(4):617-8.
 56. Verstovsek S, **Atallah E**, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. *Leukemia.* 2016 Jun;30(6):1413-5. PMID: PMC4895165
 57. Cornell RF, Zhong X, Arce-Lara C, **Atallah E**, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. *Bone Marrow Transplant.* 2015 Jul;50(7):914-7.
 58. Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, **Atallah E**, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. *Clin Lymphoma Myeloma Leuk.* 2015 Apr;15(4):214-221.e1. PMID: PMC4418454
 59. Kataria A, Cohen E, Saad E, **Atallah E**, Bresnahan B. Large granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. *Transplant Proc.* 2014 Dec;46(10):3278-81.
 60. Yan M, Geyer H, Mesa R, **Atallah E**, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. *Clin Lymphoma Myeloma Leuk.* 2015 Jan;15(1):e1-5. PMID: PMC4361182
 61. Troy JD, **Atallah E**, Geyer JT, Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. *Ann Med.* 2014 Aug;46(5):283-9.
 62. Guru Murthy GS, Pemmaraju N, **Atallah E**. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. *Leuk Res.* 2018 Oct;73:21-23.
 63. Guru Murthy GS, Pondaiah SK, Abedin S, **Atallah E**. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. *Leuk Lymphoma.* 2019 May;60(5):1171-1178.
 64. Raj RV, Abedin SM, **Atallah E**. Incorporating newer agents in the treatment of acute myeloid leukemia. *Leuk Res.* 2018 Nov;74:113-120.
 65. Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, **Atallah EL**. Implementation and evaluation of high-dose methotrexate administration guidelines. *J Oncol Pharm Pract.* 2019 Oct;25(7):1675-1681.
 66. Guru Murthy GS, **Atallah E**. Treatment-Free Remission in CML: the US Perspective. *Curr Hematol Malig Rep.* 2019 Feb;14(1):56-61.
 67. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, **Atallah E**. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. *Blood Adv.* 2019 Feb 26;3(4):508-518. PMID: PMC6391673
 68. Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, **Atallah EL**. Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. *Leuk Lymphoma.* 2019 Jun;60(6):1476-1484.
 69. Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, **Atallah E**. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. *Oncologist.* 2019 Sep;24(9):1253-1258. PMID: PMC6738285
 70. Kota V, **Atallah E**. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. *Clin Lymphoma Myeloma Leuk.* 2019 Aug;19(8):480-487.
 71. Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, **Atallah E**. Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Leuk Res. 2019 May;80:40-42.

72. **Atallah E**, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. *JAMA Oncol.* 2020 Apr 01;6(4):486-493. PMID: PMC6990739
73. Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, **Atallah E**. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. *J Natl Compr Canc Netw.* 2020 Feb;18(2):169-175.
74. Jain N, Stock W, Zeidan A, **Atallah E**, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. *Blood Adv.* 2020 Feb 11;4(3):449-457. PMID: PMC7013258
75. Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, **Atallah E**. In Reply. *Oncologist.* 2020 Apr;25(4):e744-e745. PMID: PMC7160403
76. Goldberg AD, **Atallah E**, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study *Leukemia Research.* August 2020;95.
77. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, **Atallah E**, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study *Leukemia Research.* July 2020;94.
78. Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, **Atallah E**. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. *Clin Lymphoma Myeloma Leuk.* 2020 Aug;20(8):556-560.e2.
79. Goldberg AD, **Atallah E**, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. *Leuk Res.* 2020 Aug;95:106385.
80. Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, **Atallah E**. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. *Blood Adv.* 2020 May 26;4(10):2308-2316. PMID: PMC7252553
81. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, **Atallah E**, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. *Leuk Res.* 2020 Jul;94:106368.
82. Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, **Atallah E**. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. *Cancer.* 2021 Apr 01;127(7):1039-1048.
83. **Atallah E**, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. *JAMA Oncol.* 2021 Jan 01;7(1):42-50. PMID: PMC7662490
84. **Atallah E**, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? *Haematologica.* 2020 Dec 01;105(12):2738-2745. PMID: PMC7716356
85. Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, **Atallah EL**, Guru Murthy GS. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual

- disease in relapsed/refractory acute myeloid leukemia. *Leuk Lymphoma*. 2021 Jan;62(1):158-166.
86. **Atallah EL**, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. *Leuk Lymphoma*. 2021 Jul;62(7):1730-1739.
 87. Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, **Atallah E**. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data *Bone Marrow Transplantation*. 2021.
 88. **Atallah EL**. Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making Best Practice and Research: Clinical Haematology. 2021.
 89. Schoenbeck KL, **Atallah E**, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. *J Natl Cancer Inst*. 2022 Jan 11;114(1):160-164. PMID: PMC8755495
 90. Badar T, **Atallah E**. Do histone deacetylase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? *Expert Opin Investig Drugs*. 2021 Jun;30(6):665-673.
 91. Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, **Atallah E**. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. *Bone Marrow Transplant*. 2021 Aug;56(8):1998-2004.
 92. **Atallah EL**. Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. *Best Pract Res Clin Haematol*. 2021 Mar;34(1):101240.
 93. **Atallah E**, Sweet K. Treatment-Free Remission: the New Goal in CML Therapy. *Curr Hematol Malig Rep*. 2021 Oct;16(5):433-439. PMID: PMC8495665
 94. **Atallah E**, Garcia-Manero G. Epigenetic Drugs: DNA Demethylating Agents Epigenetics in Biology and Medicine. 1 January 2008:27-48.
 95. Badar T, **Atallah E**, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. *Am J Hematol*. 2022 Jul;97(7):E232-E235.
 96. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, **Atallah E**, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. *Blood*. 2022 Jun 09;139(23):3366-3375. PMID: PMC9197557
 97. Corrao K, Rezwan S, **Atallah E**, Michaelis LC, Runaas L, Harrington AM, Abedin S. Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. *Leuk Res Rep*. 2022;17:100329. PMID: PMC9150024
 98. Guru Murthy GS, **Atallah E**. Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. *JCO Oncol Pract*. 2022 Jul;18(7):489-490.
 99. Murthy GSG, **Atallah E**. Targeting TIM-3 as a new strategy in immunotherapy: focus on sabatolimab Drugs of the Future. November 2021;46(11):901-905.
 100. Sasaki K, Mauro MJ, Levy MY, **Atallah EL**, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE. CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). *Clin Lymphoma Myeloma Leuk*. 2022 Oct;22 Suppl 2:S299.
 101. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. *J Health Econ Outcomes Res*. 2022;9(2):19-29. PMID: PMC9352872

102. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A. Chronic Myeloid Leukemia: Part II- Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. *J Health Econ Outcomes Res.* 2022;9(2):30-36. PMID: PMC9353133
103. Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, **Atallah E**. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. *J Cancer Prev.* 2022 Jun 30;27(2):129-138. PMID: PMC9271408
104. **Atallah E**. Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest? *Haematologica.* 2023 Apr 01;108(4):949-950. PMID: PMC10071108
105. Pettit K, Rezazadeh A, **Atallah EL**, Radich J. Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. *Am Soc Clin Oncol Educ Book.* 2022 Apr;42:1-19.
106. Flynn KE, **Atallah E**, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. *Haematologica.* 2022 Nov 01;107(11):2641-2649. PMID: PMC9614525
107. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States *Journal of Health Economics and Outcomes Research.* 2022;9(2):19-29.
108. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A. Chronic Myeloid Leukemia: Part II- Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective *Journal of Health Economics and Outcomes Research.* 2022;9(2):30-36.
109. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, **Atallah E**. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. *Cancer.* 2023 Mar 15;129(6):934-945.
110. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, **Atallah E**, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. *Transplant Cell Ther.* 2023 Apr;29(4):265.e1-265.e10. PMID: PMC10189888
111. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, **Atallah E**, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. *Transplant Cell Ther.* 2023 Feb;29(2):71-81.
112. Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, **Atallah E**. Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. *Leuk Res.* 2022 Dec;123:106984.
113. Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghtmour G, **Atallah EL**, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow M, Stone RM, Sharon E, Erba HP. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. *Blood Adv.* 2023 Apr 11;7(7):1279-1285. PMID: PMC10090098
114. Mikhaeel S, **Atallah E**. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). *Clin Lymphoma Myeloma Leuk.* 2023 May;23(5):333-339.
115. Badar T, **Atallah E**, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). *Leukemia.* 2023 Apr;37(4):799-806.
116. Hillis C, Flynn KE, Goldman EH, Moreira-Lucas TS, Visentini J, Dorman S, Ballinger R, Byrnes HF, De

- Palma A, Barbier V, Machado L, **Atallah E**. A Survey of Patient Experience in CML: American and Canadian Perspectives. *Patient Prefer Adherence*. 2023;17:331-347. PMID: PMC9904222
117. **Atallah E**, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. *J Cancer Res Clin Oncol*. 2023 Aug;149(9):6247-6262. PMID: PMC10356870
 118. Rezazadeh A, Deininger M, **Atallah E**. Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia Current Treatment Options in Oncology. 2023.
 119. Winn AN, **Atallah E**, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. *JAMA Netw Open*. 2023 Dec 01;6(12):e2347950. PMID: PMC10728762
 120. Held N, **Atallah EL**. Real-world Management of CML: Outcomes and Treatment Patterns. *Curr Hematol Malig Rep*. 2023 Oct;18(5):167-175.
 121. Guru Murthy GS, **Atallah E**. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. *Hematol Oncol Stem Cell Ther*. 2023 May 23;16(4):346-350.
 122. Rezazadeh A, Deininger M, **Atallah E**. Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. *Curr Treat Options Oncol*. 2023 Aug;24(8):1036-1051.
 123. Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, **Atallah EL**, Abedin SM. Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. *Leuk Res*. 2023 Sep;132:107348.
 124. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogossova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, **Atallah E**, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. *Blood Adv*. 2023 Oct 10;7(19):5941-5953. PMID: PMC10562769
 125. **Atallah E**, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with 2 tyrosine kinase inhibitors: a systematic literature review *Therapeutic Advances in Hematology*. January-December 2023;14.
 126. Badar T, Nanaa A, **Atallah E**, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) *Blood Cancer Journal*. December 2024;14(1).
 127. Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, **Atallah E**, Altman JK. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. *Am J Hematol*. 2024 Apr;99(4):606-614.
 128. **Atallah E**, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with 2 tyrosine kinase inhibitors: a systematic literature review. *Ther Adv Hematol*. 2023;14:20406207221150305. PMID: PMC10725100
 129. **Atallah E**. Eligibility criteria: too big, too small or just right? *Haematologica*. 2024 Apr 01;109(4):1021. PMID: PMC10985446
 130. Badar T, Nanaa A, **Atallah E**, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). *Blood Cancer J*. 2024 Feb 20;14(1):32. PMID: PMC10879201
 131. Muthiah C, Narra R, **Atallah E**, Juan W, Szabo A, Guru Murthy GS. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry. *Leuk Res*. 2024 May;140:107496.

Books, Chapters, and Reviews

1. **Atallah E**, Flaherty L. Treatment Of Metastatic Malignant Melanoma. Current Treatment Options in Oncology 2005; 6(3):185-193.
2. **Atallah E**, Garcia-Manero G. New Treatment Strategies in the Treatment of Myelodysplastic Syndrome. Cancer Invest. 2008 Mar;26(2):208-16
3. **Atallah E**, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clinical Advances in Hematology and Oncology 2007 Jul;5(7):544-52.
4. **Atallah E**, Schiffer CA. Granulocyte Transfusion. Current Opinion in Hematology 2006; 13(1):45-49.
5. **Atallah E**, Garcia-Manero G. The Role of Decitabine in the Treatment of Myelodysplastic Syndromes. Expert Opinion On Pharmacotherapy. Expert Opinion in Pharmacotherapy 2007 Jan;8(1):65-73.
6. **Atallah E**, Cortes J. Optimal Initial Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Current Opinion in Hematology 2007 Mar;14(2):138-44.
7. **Atallah E**, Cortes J. Emerging Safety Issues with Abl Kinase Inhibitors. Clinical Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S105-12
8. **Atallah E**. CML. Initial Therapy in Previously Untreated Patients with Chronic Myelogenous Leukemia in Chronic Phase. Clinical Leukemia, Vol. 2, No. 4, 248-251, 2008
9. **Atallah E**, Verstovsek S. The Prospect of JAK2 Inhibitor Therapy in Myeloproliferative Neoplasms. Expert review of anticancer therapy. 2009 May;9(5):663-70.
10. **Atallah E**, O'Dwyer. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Seminars in Hematology April 2009 (Vol. 46, Pages S16-S21)
11. **Atallah E**, Garcia-Manero G. Hypomethylating agents Chapter in "Epigenetics in Biology and Medicine". Editor Dr. Manel Esteller

Editorials, Letters to Editor, Other

1. **Atallah E**, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. JAK-2 mutation in patients with myelodysplastic/myeloproliferative disorders unclassifiable and refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T) is associated with good prognosis. Leukemia. 2008 Jun;22(6):1295-8.
2. **Atallah E**, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine 2007 Jan;13(1):14.
3. **Atallah E**, Schiffer CA. Agent Orange, Prostate Cancer Irradiation And Acute Promyelocytic Leukemia (APL): Is There A Link? Leukemia Research 2006.
4. Vernon M, Pearson L, **Atallah E**. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. Journal of clinical Rheumatology. 15(5):267, August 2009
5. **Atallah E**. Nilotinib cardiac toxicity: Should we still be concerned? Leuk Res. 2011 Feb 16

Non-Refereed Journal Publications/Original Papers

1. **Atallah E**, O'Dwyer. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol. 2009 Apr;46(2 Suppl 3):S16-21

Abstracts

1. **Atallah E**, Uberti J, Ayash L, Bentley G, VanDahm J, Ratanatharathorn V. Fifteen-Year Follow up of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes Using Busulfan-Based Regimens. ASH Annual Meeting Abstracts 2005; 106(11):5461.
2. **Atallah E**, Kantarjian H, De Lima M, Borthakur G, Wierda W, Champlin R, Cortes J. The Role of Dasatinib in Patients with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Relapsing after Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 4520.
3. **Atallah E**, O'Brien S, Kaled S, Lynn A, Cortes J, Kantarjian H, Thomas D
4. Traumatic Lumbar Puncture (TLP) Is Not Associated with Worse Outcome in Adults with Acute Lymphocytic Leukemia (ALL) or Burkitt-Type Leukemia/Lymphoma (BLL) Receiving Hyper-CVAD Regimens. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4346.
5. **Atallah E**, O'Brien S, Kaled S, Lynn A, Cortes J, Kantarjian H, Thomas D
6. Safety of Lumbar Puncture (LP) and Instillation of Intrathecal (IT) Chemotherapy during Thrombocytopenia in Adults with Acute Lymphocytic Leukemia (ALL).
7. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4347.

8. Jasleen K Randhawa, MD, Christopher Bredeson, MD2, Timothy S. Fenske, MD2, Ayman Saad, MD3, Jeanne Palmer, MD4, Parameswaran N Hari, MD5, Horatiu Olteanu*,6 and Ehab Atallah, MD2. Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4157.

Peer Reviewed Educational Products

1. **Atallah E**, Tam C, O'Brien S. CLL the cutting edge. CME educational activity